Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL871688 | 0.98 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2109932 | 0.93 | STS (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL24861978 | 0.93 | AKT1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18662857 | 0.93 | AKT1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19331211 | 0.89 | ALDH1A1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19343523 | 0.84 | NPC1 (0.48) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19343552 | 0.82 | ALDH1A1 (0.44) | CA1CA2CA12CA9CA14 | |
| SCHEMBL17508491 | 0.81 | LMNA (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2672851 | 0.81 | CA12 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL8256047 | 0.81 | CA12 (0.56) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-09-02 | — | — | US | claimed |
| EP-4126821-B1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech Srl (IT) | 2024-05-15 | — | — | EP | claimed |
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-08-08 | — | — | US | claimed |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-04-27 | — | — | US | claimed |
| EP-3820842-B1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech Srl (IT) | 2023-03-29 | — | — | EP | claimed |
| EP-4126821-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech S.r.l. (IT) | 2023-02-08 | — | — | EP | claimed |
| CN-115515936-A | Process for the preparation of (R) -4- (1- (6- (4- (trifluoromethyl) benzyl) -6-azaspiro [2.5] octane-5-carboxamido) -cyclopropyl) benzoic acid or a salt thereof | 罗达制药生物技术有限责任公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2021191062-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-09-30 | — | — | WO | claimed |
| EP-3885339-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech S.r.l. (IT) | 2021-09-29 | — | — | EP | claimed |
| EP-3820842-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech S.r.l. (IT) | 2021-05-19 | — | — | EP | claimed |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-05-06 | — | — | US | claimed |
| CN-112638871-A | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020012305-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-01-16 | — | — | WO | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260070918-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| WO-2009020588-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVE | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | CA1 1070/4885CA2 668/4885CA12 3220/4885 |
| US-20260070918-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | PTGER1, PTGER4, PTGER2 | CA1 2864/4885CA2 1713/4885CA12 2949/4885 |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | CA1 1919/4885CA2 442/4885CA12 1673/4885 |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | PTGER4, PTGER1, PTGER2 | CA1 1070/4885CA2 668/4885CA12 3220/4885 |
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | BACH1, ADH1C, ADH1A | CA1 974/4885CA2 1422/4885CA12 796/4885 |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | BACH1, ADH1C, ADH1A | CA1 974/4885CA2 1422/4885CA12 796/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | CA1 4007/4885CA2 1544/4885CA12 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.